Logo image of OSTX

OS THERAPIES INC (OSTX) Stock Price, Quote, News and Overview

NYSEARCA:OSTX - NYSE Arca - US68764Y2072 - Common Stock - Currency: USD

1.89  +0.03 (+1.61%)

After market: 1.8218 -0.07 (-3.61%)

OSTX Quote, Performance and Key Statistics

OS THERAPIES INC

NYSEARCA:OSTX (2/20/2025, 8:04:03 PM)

After market: 1.8218 -0.07 (-3.61%)

1.89

+0.03 (+1.61%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap40.14M
Shares21.24M
Float14.35M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE2.62
Earnings (Next)N/A N/A
IPO08-01 2024-08-01


OSTX short term performance overview.The bars show the price performance of OSTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

OSTX long term performance overview.The bars show the price performance of OSTX in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of OSTX is 1.89 USD. In the past month the price decreased by -37.62%.

OS THERAPIES INC / OSTX Daily stock chart

OSTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.85 354.98B
AMGN AMGEN INC 15.03 159.99B
GILD GILEAD SCIENCES INC 23.87 137.10B
VRTX VERTEX PHARMACEUTICALS INC 1656.31 123.40B
REGN REGENERON PHARMACEUTICALS 15.25 76.09B
ARGX ARGENX SE - ADR N/A 39.34B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.37B
BNTX BIONTECH SE-ADR N/A 28.26B
ONC BEIGENE LTD-ADR N/A 26.06B
NTRA NATERA INC N/A 22.20B
BIIB BIOGEN INC 8.32 19.98B
SMMT SUMMIT THERAPEUTICS INC N/A 17.01B

About OSTX

Company Profile

OSTX logo image OS Therapies Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. OS Therapies Incorporated is a clinical-stage biopharmaceutical company. The firm is focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company built a pipeline of product candidates targeting multiple indications for solid cancers. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. OST-HER2 is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH sensitive silicone linkers (SiLinkers). The payloads can include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments directly into and in the vicinity of solid tumors.

Company Info

OS THERAPIES INC

15825 Shady Grove Road, Suite 135

Rockville MARYLAND US

Employees: 4

Company Website: https://ostherapies.com/

Phone: 14102977793

OS THERAPIES INC / OSTX FAQ

What is the stock price of OS THERAPIES INC today?

The current stock price of OSTX is 1.89 USD. The price increased by 1.61% in the last trading session.


What is the ticker symbol for OS THERAPIES INC stock?

The exchange symbol of OS THERAPIES INC is OSTX and it is listed on the NYSE Arca exchange.


On which exchange is OSTX stock listed?

OSTX stock is listed on the NYSE Arca exchange.


What is the price forecast or stock price prediction for OS THERAPIES INC stock?

9 analysts have analysed OSTX and the average price target is 14.96 USD. This implies a price increase of 691.53% is expected in the next year compared to the current price of 1.89. Check the OS THERAPIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is OS THERAPIES INC worth?

OS THERAPIES INC (OSTX) has a market capitalization of 40.14M USD. This makes OSTX a Nano Cap stock.


How many employees does OS THERAPIES INC have?

OS THERAPIES INC (OSTX) currently has 4 employees.


What are the support and resistance levels for OS THERAPIES INC (OSTX) stock?

OS THERAPIES INC (OSTX) has a support level at 1.88. Check the full technical report for a detailed analysis of OSTX support and resistance levels.


Should I buy OS THERAPIES INC (OSTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does OS THERAPIES INC (OSTX) stock pay dividends?

OSTX does not pay a dividend.


What is the Price/Earnings (PE) ratio of OS THERAPIES INC (OSTX)?

OS THERAPIES INC (OSTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.36).


What is the Short Interest ratio of OS THERAPIES INC (OSTX) stock?

The outstanding short interest for OS THERAPIES INC (OSTX) is 1.83% of its float. Check the ownership tab for more information on the OSTX short interest.


OSTX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to OSTX.


Chartmill TA Rating
Chartmill Setup Rating

OSTX Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to OSTX. OSTX has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OSTX Financial Highlights

Over the last trailing twelve months OSTX reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS decreased by -40.49% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -375.2%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)-40.49%
Revenue 1Y (TTM)N/A

OSTX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to OSTX. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst OwnersN/A
Ins Owners24.84%
Short Float %1.83%
Short Ratio0.19
Analysts
Analysts82.22
Price Target14.96 (691.53%)
EPS Next Y-182.72%
Revenue Next YearN/A